Awarding of the German National Prize 2025 BioNTech co-founder honored with the German National Prize

Germany Friedrich Merz · Chancellor of Germany

10 June 2025 · Awarding of the German National Prize 2025 · Berlin, Germany

Context
Merz addressed the German National Foundation ceremony on June 10, 2025, honoring BioNTech co-founders Özlem Türeci and Uğur Şahin with the German National Prize.
Main themes
MRNA technology and innovation, BioNTech and COVID-19 vaccine development, cancer research and immunotherapy, scientific courage and entrepreneurship, history of medical progress, German scientific legacy, Project Lightspeed, pioneers of modern medicine
Duration
~22 min
71st percentile
Words
2,670
71st percentile
Sentences
183
87th percentile
Readability
58
84th percentile
Grade
9.0
11th percentile
Syntax
2.64
9th percentile
Vocabulary
2.68
98th percentile

Translated from German

Content
Actors
Style

The broad sphere of national life a sentence belongs to. Every sentence has an Arena, so it is the denominator the other indices are read against.

Other
  • Social 41%40%
  • Ceremonial 33%32%
  • Economic 17%17%
  • Technological 6%6%
  • Institutional 3%3%
  • Geopolitical 1%1%
  • Environmental 0%0%
  • Not in focus 1%

183 sentences in 88 paragraphs

Dear Mr. Chairman, dear Dr. Mirow,

esteemed members of the Board, the Senate, and the Board of Trustees of the German National Foundation,

Madam Federal Minister,

dear colleagues from the parliaments,

but above all, esteemed, dear Professor

Türeci

,

esteemed, dear Professor

Şahin

,

if you should decide this evening to take a little walk from here towards the Brandenburg Gate, and just before it turn right, heading north, you will eventually pass by the Rahel Hirsch

Center for Translational Medicine and shortly thereafter arrive at Robert-Koch-Platz. If you then continue walking a bit further northwest, you will eventually pass by the

Charité

-Virchow-Klinikum campus. From there, a little further east, you will quickly find yourself on Behringstraße. Throughout Berlin, and likely similarly in most German cities, squares and streets bear the names of great pioneers of medicine. There is a reason for these names. The face of the modern world we live in today is shaped by the discoveries and achievements of modern medicine. We live, at least in Europe, largely free from plague, smallpox, polio, rubella, and even measles. We have antibiotics. We have vaccines. As a result, in just the last 150 years, the average life expectancy in Europe has nearly doubled.

The history of modernity is thus also, and above all, the history of medical progress. That is why we know the names so well that are associated with it, namely Robert Koch, Rudolf Virchow, Emil von Behring, Alexander Fleming, Gerty Cori, Rachel Hirsch. Many German names are among them.

Dear

Özlem Türeci

, dear

Uğur Şahin

, in this line of great German names, great German researchers, you both stand as well. Today, we honor two pioneers, two trailblazers of our modern medicine with you. We honor your extraordinary courage to repeatedly make decisions and take paths into the unknown for which there is no map yet.

You chose to pursue the opportunities of the new mRNA technology for immunotherapeutic cancer treatment at a time when many others saw the risks. You decided to found two companies to bring your promising research results to patients more quickly. First

Ganymed Pharmaceuticals

, and in 2008, the founding of BioNTech followed.

Then, in 2020, another decision with which you both – one can say without any exaggeration – made history. It is a Friday evening at the end of January. The outbreak of a new respiratory disease in Wuhan, China, has been known for three weeks.

Uğur Şahin

reads about the virus SARS-CoV-2 in a scientific journal. Over the weekend, you both discuss. You see the danger of a pandemic while others still consider it a limited outbreak. At the same time, you see that based on your mRNA research, it might be possible to develop an effective vaccine against this virus. You decide to try, even though a failure would almost certainly have brought BioNTech to an end. You immediately begin work, starting on Monday. Project

Lightspeed

is launched.

Eight years, that is how long the development of a new vaccine usually takes on average. You both and your team developed the COVID-19 vaccine, which the whole world is now waiting for, in less than a year. It is a record, and it is a medical revolution, a revolution that saves millions of lives.

Where do you both find the courage for such decisions? Surely, your scientific ethos has something to do with it. You are both scientists with body and soul.

Uğur Şahin

said in an interview in 2022 that science means venturing into the unknown. Yes, ladies and gentlemen, thinking ahead, not settling for what is seemingly a necessity, yes, fate, perhaps unchangeable, but rather getting to work, seeking solutions, has always been the driving force of scientific work. It is the driving force of progress and modernity.

I imagine that as a cancer researcher, one must be particularly equipped with this resilience, with this unwavering will to find solutions. Cancer stands like no other disease for a largely insurmountable stroke of fate. The name of the disease alone is so full of horror that it was common until well into the second half of the 20th century for doctors to withhold the diagnosis from their patients. Even today, cancer is often spoken of in hushed tones. Statistically, every second German will be diagnosed with cancer in their lifetime, and each of us here today knows people in our family, among friends, and acquaintances who have suffered from cancer and passed away. Chemotherapy, too, is a term that frightens many people.

However, the research and entrepreneurial work of

Özlem Türeci

and

Uğur Şahin

have made a future conceivable in which these images could belong to the past, and in which cancer could lose its terror. According to many experts, we are facing another true medical revolution with mRNA vaccines – possibly at the beginning of successful cancer treatment. And all of this is only because you both,

Özlem Türeci

and

Uğur Şahin

, have repeatedly chosen to venture into the unknown.

From this courage and this scientific ethos, ladies and gentlemen, we can and should all learn – especially we in politics. Pragmatism may be a political virtue, but under the guise of pragmatism, it often happens in politics that we simply give up the will to truly shape something fundamental.

Yes, good politics acknowledges reality, and good politics also recognizes that social change takes time, that societies have their own pace, which is not always “

light speed

,” because innovations – no matter how beneficial they may be for the common good – must be communicated. This is also a lesson we can draw from the COVID-19 pandemic.

But acknowledging reality must not mean simply settling for the status quo – especially not when it leaves much to be desired – or merely asserting supposed necessities. Under such premises, politics will always only be playing catch-up with events instead of moving forward and making the world better for people.

It was the overly optimistic premise of the end of history that gave us a comparable image of the supposedly unstoppable development of our societies towards freedom, peace, the rule of law, and democracy – a premise that lulled us into a false sense of security for two decades.

However, from this disillusioned illusion of security, a new fatalism must not arise. War, upheavals in our social orders are spoken of as once about plagues – and as sometimes still today about cancer: as inevitability, as inescapable fate, as a historical law.

In the political realm, in our societies overall, ladies and gentlemen, the optimism of progress that once drove modernity seems to be exhausted. We seem to be losing the joy of shaping our future. This is how many observers describe it. And it seems almost paradoxical: The progress being made today in modern technologies, especially in medicine, is overwhelming. It is advancing in quantum leaps. But the enthusiasm for it remains rather limited in our societies, which are sometimes already labeled as “postmodern.”

Esteemed, dear

Özlem Türeci

, esteemed, dear

Uğur Şahin

, ladies and gentlemen, it is my firm conviction that in this situation, it is our task, in politics and as a society overall, to think forward, to open our horizons in our minds, in our thinking – so that confidence can once again become possible throughout our country.

Perhaps I may share with you what enables me to continually remember this task: It is indeed the visit to great research institutions – whether at universities or in companies – where future research is conducted. But these are also training companies where young people joyfully and passionately learn a profession, create a first piece of work. And it is the conversation with scientists, with leading researchers, with pioneers like

Uğur Şahin

and

Özlem Türeci

.

We honor you both today for your great contributions to virological research. But we also honor you because we want to be inspired by your courage, your diligence, your passion for the cause, your unwavering curiosity, because we want to be inspired as a society by you. You both embody the future strength of a free society – as scientists seeking solutions, but also as entrepreneurs for whom responsibility is at the center of their work.

You have become entrepreneurs to bring your research to patients as quickly as possible. You invest profits in the development of new ideas and technologies. You both provide daily proof that entrepreneurship, when properly understood, is also work for the common good.

The speed at which BioNTech developed the COVID vaccine would not have been possible in a state apparatus. We know from experience: Innovation and thus progress only arise where there is room for researchers and developers, for people with visions, willpower, courage, and foresight.

Özlem Türeci

and

Uğur Şahin

embody this future strength of a free society, and they show what citizens of our country with a migration background are capable of. You are both children of Turkish immigrants. Your father, dear Ms.

Özlem Türeci

, worked as a surgeon in a small Catholic hospital. Your father, dear Mr.

Uğur Şahin

, worked at the Ford plant in Cologne as one of the more than 14 million “guest workers,” as they used to say, who came to Germany in the 1960s and 1970s and who significantly contributed to the prosperity of our country.

This first generation of immigrants has received little recognition for this to this day.

Uğur Şahin

once referred to this first generation of Turkish immigrants in an interview as an “ignored generation.” That is a sentence one does not forget.

Today we know better. We must do much better, especially with regard to the younger generation.

“How can we support children? How can we enable children to utilize their abilities and develop further and then contribute to society?”

Ladies and gentlemen, this is also a quote from

Uğur Şahin

. He graduated from high school in 1984 at a gymnasium in Cologne as the first Turkish guest worker child, and he was also the best in his class.

Let me connect exactly to that: I want, we want to live in a Germany where talents and abilities are promoted to the fullest, regardless of social or ethnic background, and not only because this could be a growth driver for our economy, but above all because it is about the central promise from which the radiance of a free society can develop, namely the promise that everyone can develop freely with their talents and abilities. Today, more than 80 nations are represented at BioNTech. This is also part of your success. It shows once again: As a national economy, we need qualified immigration. We need skilled labor immigration as a motor of progress. Ideologies and ideologists that question this not only endanger the prosperity of our country, but much worse, they jeopardize the future of our free order with their narrow-mindedness.

Ladies and gentlemen, therefore, in the coming years, it will be a central task for the federal government to create conditions in Germany and Europe for science, research, and development that can keep pace with all – I emphasize: with all – research-intensive locations in the world. We were once the most successful pharmaceutical location in the world. Germany called itself the pharmacy of the world. We could reconnect with these successes of the past today if we all remove our blinders and allow research and development, especially in the field of biotechnology, as has been achieved by BioNTech in recent years.

Germany is a science nation. We have a highly innovative scientific landscape. But we must improve as a country, translating our top research more quickly into patents and into products, medications, treatment methods, and medical technology from interdisciplinary research and development. You, dear

Özlem Türeci

You once said in an interview that the technological revolution of the present requires fast processes to bring innovative therapies to patients sooner, and you both have been calling for years: We need to modernize our drug development routines in Germany, in Europe, so that they do not become a bottleneck for medical innovation. – I would like to respond: We in politics hear you. We will focus our efforts on eliminating this bottleneck, and we will also need to discuss the financing of this medical and technological progress together. Our system must become overall more efficient and equitable in terms of performance, and indeed all people should be able to participate in this progress.

But, ladies and gentlemen, our health policy is far too often under the heading of a cost burden. This heading certainly has some justification. However, the health sector as a whole, with all its services, is also the fastest-growing sector of our economy. Therefore, understanding the health sector not just as a cost factor, but as a growth engine and a driver of prosperity is at least equally important, especially when we look at the great opportunities of a global market, where the competition for these innovations is taking place more than ever.

With that, I return to you, dear award winners. A few days ago, you concluded an agreement with a large American company for the further development of one of your most promising drug candidates for cancer treatment. You can invest several billion US dollars in research over the next few years. With this, your company has finally arrived in the top league of research-based pharmaceutical companies in the world. May I say it this way? May I say it this way, ladies and gentlemen, and also on behalf of all of you? We are truly proud of you! We are happy. We are happy with you.

Now let me address one last issue that concerns me, but which also describes another task that we can only solve politically. You probably all know: BioNTech is a publicly traded corporation. But not all of you may know that the IPO took place just over six years ago, despite the founding and location of the company in Germany, in the USA, more precisely in New York on the NASDAQ technology exchange. Not many companies from Germany achieve this, and it is a great honor for BioNTech to this day. However, this IPO also shows that we need to improve in shaping a European capital market that must enable such IPOs in the future in Germany or, better said, in Europe; because this would keep important parts of the value creation of such companies in Europe and, above all, increase the prosperity of our societies through the capital market. This task must be taken on by us in politics, and rest assured that I am firmly determined to do so; because only then will the success story of these companies be truly complete, to put it casually, when research, innovation, patents, and products come from Germany and Europe just as the accompanying prosperity remains primarily in Germany and Europe through the capital market. But you two, esteemed award winners, do not need to worry about that. We will take care of it.

All that remains for us today is to congratulate you from the bottom of our hearts and to award you the German National Prize 2025. In our society, we award prizes, ladies and gentlemen, to remind ourselves of what is important to us, what values we stand for, what goals we have, what is exemplary for us. Today, we honor two outstanding researchers and entrepreneurs, two pioneers who set global standards in their field of research and who show us as a society in Germany what is possible when people decide to make things better. You both remind us that Germany can be a country from which solutions for humanity's challenges come, thus progress, and the future. It is a special honor for me personally to present you with this award today on behalf of the German National Foundation. We all congratulate you, and we are truly grateful to you.